0001515768-14-000003.txt : 20140403 0001515768-14-000003.hdr.sgml : 20140403 20140403151901 ACCESSION NUMBER: 0001515768-14-000003 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20140403 DATE AS OF CHANGE: 20140403 EFFECTIVENESS DATE: 20140403 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ABATTIS BIOCEUTICALS CORP CENTRAL INDEX KEY: 0001515768 IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 0930 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-214864 FILM NUMBER: 14741894 BUSINESS ADDRESS: STREET 1: SUITE 1000 - 355 BURRARD STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 2G8 BUSINESS PHONE: 604-538-6650 MAIL ADDRESS: STREET 1: SUITE 1000 - 355 BURRARD STREET CITY: VANCOUVER STATE: A1 ZIP: V6C 2G8 FORMER COMPANY: FORMER CONFORMED NAME: ABATTIS BIOLOGIX Corp DATE OF NAME CHANGE: 20110316 D 1 primary_doc.xml X0707 D LIVE 0001515768 ABATTIS BIOCEUTICALS CORP SUITE 1000 - 355 BURRARD STREET VANCOUVER A1 BRITISH COLUMBIA, CANADA V6C 2G8 604-538-6650 BRITISH COLUMBIA, CANADA ABATTIS BIOLOGIX Corp Corporation true Mike Withrow SUITE 1000 - 355 BURRARD STREET Vancouver A1 BRITISH COLUMBIA, CANADA V6C 2G8 Executive Officer Director Tim Fealey SUITE 1000 - 355 BURRARD STREET Vancouver A1 BRITISH COLUMBIA, CANADA V6C 2G8 Director Douglas J. Sorocco SUITE 1000 - 355 BURRARD STREET Vancouver A1 BRITISH COLUMBIA, CANADA V6C 2G8 Director Robert Hedley SUITE 1000 - 355 BURRARD STREET Vancouver A1 BRITISH COLUMBIA, CANADA V6C 2G8 Director Rene David SUITE 1000 - 355 BURRARD STREET Vancouver A1 BRITISH COLUMBIA, CANADA V6C 2G8 Executive Officer Other Health Care $1 - $1,000,000 06b false 2014-03-18 true true true true true Each unit is comprised of one common share and one share purchase warrant. Each warrant is exercisable for one common share at an exercise price of Cdn$0.50 for a period of eighteen months, subject to acceleration. false 0 2489145 83709 2405436 The additional $2,405,436 may be received upon the exercise of share purchase warrants sold inside and outside the U.S. U.S. dollar amounts are based on the Bank of Canada noon rate of exchange reported on March 18, 2014, which was Cdn$1.1086=US$1.00. false 6 0 0 0 In the ordinary course of business, the issuer may use some of the proceeds of the offering to pay salaries to certain of its executive officers and directors. false ABATTIS BIOCEUTICALS CORP /s/ Mike Withrow Mike Withrow Chief Executive Officer and President 2014-04-01